FDA Panel Backs New Use of Amgen’s Neupogen
- Share via
A Food and Drug Administration advisory panel has recommended expanding the use of Amgen Inc.’s Neupogen drug.
If the FDA approves a unanimous decision by its Biological Response Modifier Advisory Committee, Neupogen will be used for more rapid recovery of white blood cells after some forms of cancer chemotherapy.
The new procedure would allow cells to be removed from a patient’s blood instead of from bone marrow. Removal from the blood is less invasive and can be done on an outpatient basis, Amgen said.
Neupogen is a key product of the Thousand Oaks-based biotechnology company.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.